Free tool
FAERS Monitor: Neuraceq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204677 or its brand name (Neuraceq, Florbetaben F-18). Reports on generic versions are filed under their own applications.
Reports
21
Serious
5
24% of reports
Hospitalization
2
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- amyloid related imaging abnormality-oedema/effusion6
- burning sensation4
- injection site pain4
- asthenia3
- fatigue3
- infusion related reaction3
- discomfort2
- dizziness2
- dyspnoea2
- headache2
- hyperhidrosis2
- nausea2
- accidental underdose1
- amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits1
- aphasia1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2023 | 7 |
| 2024 | 2 |
| 2025 | 6 |
| 2026 | 5 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,138 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| amyloid related imaging abnormality-oedema/effusionSignal | 6 | 4914.6 | 2493.4 | 24,647 |
| amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits | 1 | 935.2 | 138.0 | 233 |
| accidental underdose | 1 | 69.6 | 10.3 | 16 |
| burning sensationSignal | 4 | 57.1 | 23.7 | 169 |
| infusion related reactionSignal | 3 | 45.3 | 15.9 | 90 |
| aphasia | 1 | 33.2 | 4.9 | 7 |
| discomfort | 2 | 32.8 | 8.8 | 34 |
| hyperhidrosis | 2 | 15.6 | 4.2 | 15 |
| injection site painSignal | 4 | 13.1 | 5.4 | 34 |
| astheniaSignal | 3 | 8.0 | 2.8 | 12 |
| dizziness | 2 | 4.0 | 1.1 | 2 |
| fatigue | 3 | 3.9 | 1.4 | 4 |
| dyspnoea | 2 | 3.5 | 0.9 | 2 |
| headache | 2 | 3.2 | 0.9 | 1 |
| nausea | 2 | 2.5 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.